Aims: To compare the management of patients with diabetes and heart failure with reduced ejection fraction (HFrEF) in the United States and Asia to understand variations in treatment patterns across different healthcare systems.
failure (HF) and diabetes often coexist, [1] [2] [3] but affected patients are at particularly high risk of morbidity and mortality. 2, 4 They often require complex medication regimens, with several physicians managing their care, and certain treatments for one disease may complicate the other.
For example, thiazolidinediones (TZDs) 5, 6 can lead to volume overload and increased risk of hospitalization for HF. Glucose-lowering medications with increased risk of hypoglycaemic events (eg, insulin and sulphonylureas) have been associated with increased morbidity and mortality in patients with HF, 7 whereas medications such as sodiumglucose co-transporter-2 (SGLT2) inhibitors, and possibly metformin, may be of benefit to patients with HF. 8, 9 Conversely, guidelinedirected medical therapy for HFrEF may impact glycaemic control (eg, 2 | METHODS
| Patient population
Our study population was derived from two large registries: the Diabetes Collaborative Registry (DCR) 10 and the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. 11 The DCR is an on-going, United States-based, quality improvement registry that began in 2014
(with data collected retrospectively from 2013) and includes patients with diabetes who are seen in enrolling primary care, cardiology and endocrinology outpatient offices. Patient data are extracted from electronic health records, and the DCR currently includes 374 practices and 5114 providers. 10 Because participation in the DCR requires no data collection beyond that conducted in routine clinical care and as collected data are de-identified, a waiver of written informed consent and authorization for the present study was granted by Chesa- 3 | RESULTS
| Study cohort
Among 657 608 US adults with diabetes who were seen in a DCR- There were a number of demographic and clinical differences among the groups (Table 1) .
Patients with diabetes and HFrEF in the United
States were more likely to be older and women than patients from both HI and LI Asian countries. US patients also had more cardiac comorbidities, with more hypertension, coronary artery disease, peripheral artery disease, cerebrovascular disease and atrial fibrillation. US patients were more likely to be current or former smokers and had higher body mass indices.
| HF characteristics and management
The mean left ventricular ejection fraction was similar among groups, use of TZDs was 5.6% in US patients (P < 0.001). Glucagon-like peptide-1 (GLP-1) receptor agonists and SGLT2 inhibitors were prescribed in only 3.8% and 2.0% of US patients with HFrEF, respectively, but these medications were almost never used in Asia during the study period (HI Asian countries: 0.4% and 0.3%, respectively; LI Asian countries: 0.0% for both; P < 0.001 for both). Patients with both HFrEF and diabetes are some of the more complex patients to manage because of the number of medications required to treat each condition and the impact that the medications for one condition may have on the other condition. In higher-income countries, it is also common for these patients to be managed by a Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CRT, cardiac resynchronization therapy; HF, heart failure; HI, high-income; ICD, implantable cardiac defibrillator; LI, low-income. a Diabetes/HF-specific = carvedilol, other HF-specific = metoprolol or bisoprolol, non-HF-specific = all others. There are a number of potential limitations to the present analyses that should be addressed. First, the DCR and ASIAN-HF registry are structured differently, with the former being a large, electronic health record database with a focus on diabetes and the latter being a smaller prospective registry focused on HF. As such, there were notable differences in the sample sizes of the two registries, and we were not able to compare a number of data elements across data sources. were selected based on country size, geographic location within the country, patient population served, and delivery of high quality of data, with minimal missing data, thus probably reflecting higher quality clinical care than that which is generally seen as a local standard. Furthermore, as the ASIAN-HF database was a prospective registry requiring active enrolment, there was the potential for selection bias.
| DISCUSSION
Our results may therefore underestimate the gaps in care quality across both geographic regions. Third, we were unable to distinguish metoprolol tartrate from succinate in the DCR, therefore, some patients were probably inappropriately considered as being on HFspecific β-blockers. Finally, while we were able to identify different practice patterns across geographic regions, we were unable to explore the reasons underlying these differences. While some of the treatment differences appear to be influenced by economic constraints (particularly in LI Asian countries), the reasons behind particular treatment choices are often multifactorial and could be driven by differences in patient preferences (eg, lower use of injectables in Asia), access to newer medications in countries with national healthcare (eg, low use of SGLT2 inhibitors and GLP-1 receptor agonists in Asia), pharmaceutical-driven market forces (eg, strong push for use of carvedilol in the United States in previous years), comorbidities (eg, less obesity and coronary disease in Asia or differences in advanced chronic kidney disease), or a number of other patient, provider and system factors. Specifically, we were unable to explore variables that may account for differences in prescribing patterns for guidelinedirected medical therapy, such as age, sex, New York Heart Association class, renal function, HbA1c, concomitant medications, body mass index, blood pressure and duration of HF (which might be longer in the ASIAN-HF database because of the 3-year data collection).
In conclusion, we identified differences in both diabetes and HFrEF treatment patterns in patients with both conditions from registries in the United States and Asia. While some practice patterns may be driven by economic constraints, others may be the result of suboptimal education, patient preferences or market forces that vary across healthcare systems. Practice patterns are not ideal in either the United
States or Asia, with opportunities for improvement in the use of evidence-based therapies for both conditions. Given these patients' complex medication regimens with cross-condition effects, effective tools are needed to help providers navigate these medication choices.
Furthermore, while patients with diabetes and HFrEF often have multiple other comorbidities that make them challenging patients to study, more research is needed to understand how medications impact these specific patients, as extrapolation from trials which exclude multiple comorbidities may not accurately apply to the realworld setting.
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